Please visit clinicaltrials.gov for detailed information about our ongoing clinical trials.
NAVIGATING THE UNFAMILIAR WATERS OF CLINICAL TRIALS
If you feel that finding information about clinical trials is similar to the experience of sailing through deep unfamiliar waters while facing the stiff headwinds of incomprehension, you are not alone. What follows is your “message in a bottle” to guide you to safe port.
Participation in a clinical trial is strictly voluntary. Once enrolled, you can withdraw at anytime. It is a requirement to sign an “informed consent” document explaining the risks and potential benefits of the trial.
The beneficiaries of clinical trials are not just medical researchers but also you, the patient, due to early access to additional treatment options that would not otherwise be available.
EPICENTRX CLINICAL TRIALS
Study: RRx-001 in Small, Non-small Cell Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens
Conditions: Small Cell Lung Carcinoma;Carcinoma, Non-Small-Cell Lung, Ovarian Cancer; Neuroendocrine Tumors
Interventions: Drug: RRx-001; Drug: Cisplatin/carboplatin plus albumin (nab-paclitaxel or Abraxane); Drug: cisplatin/carboplatin plus etoposide
Study: A Phase I, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
Conditions: Malignant Solid Tumor
Interventions: Drug: RRx-001; Drug: Irinotecan
Study: Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
Conditions: Glioblastoma and Anaplastic Gliomas
Interventions: RRx-001 + Radiation + Temozolomide